Abstract
Phase 1 Study of the Novel Kinesin Spindle Protein Inhibitor Filanesib + Carfilzomib in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have